Semax: Mechanism, Research Uses and Handling Guide

Author : Zubair Arain | Published On : 08 Oct 2026

Semax: Mechanism, Research Applications and Handling Requirements

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, designed as a stabilised analogue of a fragment of adrenocorticotropic hormone (ACTH). It was developed in Russia and has been studied in laboratory models for its effects on neurotrophin expression, gene transcription after experimental ischaemia, and monoaminergic signalling in the rodent brain. It is a research tool for neurobiology, peptide stability and analytical chemistry. This article sets out its structure, the proposed mechanisms, the published preclinical literature, its laboratory applications, and the purity, storage and handling requirements that apply to it as a research-use-only material.

What is Semax?

Semax is a synthetic oligopeptide of seven amino acids. Its sequence is methionine, glutamic acid, histidine, phenylalanine, proline, glycine and proline (MEHFPGP). The molecular formula is C37H51N9O10S and the average molecular weight is approximately 813.9 daltons, which places it among the smaller research peptides and makes it straightforward to characterise by liquid chromatography and mass spectrometry.

The peptide is derived from the ACTH(4-10) fragment, whose sequence is Met-Glu-His-Phe-Arg-Trp-Gly. In the analogue, the Arg-Trp-Gly portion is replaced by the tripeptide Pro-Gly-Pro. This C-terminal modification was introduced to slow enzymatic breakdown. Short linear peptides are rapidly cleaved by exopeptidases in biological fluids, and a terminal Pro-Gly-Pro sequence is more resistant to that attack than the native fragment. The ACTH(4-10) region is also notable because it lacks the part of the hormone responsible for stimulating the adrenal cortex, so the analogue was designed to retain the fragment's neuroactive properties in animal models without corticotropic activity.

Semax was developed during the 1980s by Russian researchers working at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, within a broader programme to create stable analogues of regulatory peptides. Most of the published preclinical work on the compound comes from Russian laboratories, which is worth bearing in mind when assessing the breadth of independent replication.

Because it is built from standard proteinogenic residues, Semax is made by routine Fmoc solid-phase peptide synthesis. The resin-bound chain is assembled from the C-terminus, cleaved with trifluoroacetic acid, purified by reversed-phase HPLC and lyophilised. The presence of methionine, histidine and phenylalanine in the sequence has practical consequences for stability and analysis, discussed below.

Mechanism of action

The mechanism of Semax is not fully resolved, and the literature describes several overlapping observations rather than a single established receptor interaction. Because it derives from an ACTH fragment, an interaction with the melanocortin receptor family is the obvious hypothesis. Melanocortin receptors are G protein-coupled receptors that signal chiefly through Gs and adenylyl cyclase to raise intracellular cyclic AMP, and several subtypes are expressed in the central nervous system. However, the ACTH(4-10) core is not the high-affinity binding region for these receptors, and the evidence for direct, potent melanocortin receptor activation by this peptide is limited. Researchers should therefore treat melanocortin signalling as a proposed pathway rather than a confirmed one.

The better-documented observations concern downstream effects. Rodent studies have reported that the peptide alters the expression of brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin receptor kinase B (TrkB), in the hippocampus. BDNF-TrkB signalling is a central pathway in neuronal survival, synaptic plasticity and dendritic growth, so changes in this axis are of interest to neuroscience laboratories regardless of the upstream trigger. Other work has reported modulation of dopaminergic and serotonergic activity in rodent brain regions, and changes in the transcription of genes linked to immune and vascular function in experimental ischaemia models.

A further consideration is metabolism. The intact heptapeptide may not be the only active species. Proteolytic fragments, including those containing the Pro-Gly-Pro motif, have themselves been studied in rodent models, and some of the effects attributed to the parent molecule may reflect its breakdown products. This is why peptide stability and degradation profiles feature in the research literature, and why the identity and purity of the starting material matter. A preparation contaminated with oxidised or truncated forms may produce a different pharmacological signal from the intended sequence, which would confound any attempt to relate observed effects to the heptapeptide itself.

What the research shows

The preclinical literature on Semax is concentrated in rodent models and in cell and tissue analysis. The summaries below describe the research in general terms, and readers should consult the original papers for methods, doses and statistics. Dosing in these studies varied by route and model, and is described here only as reported in animals.

The first area concerns neurotrophins in the hippocampus. Dolotov and colleagues, working with Russian collaborators, reported in the journal Brain Research in 2006 that administering the peptide to rats altered the expression of BDNF and its receptor TrkB in the hippocampus. The model was healthy adult rats, and the observation was an increase in neurotrophin pathway components in that brain region following administration. The work is frequently cited as a basis for interest in the compound as a probe of BDNF regulation. The paper can be located through a PubMed search for the 2006 Dolotov study on BDNF and TrkB expression.

The second area is gene expression after experimental cerebral ischaemia. Stavchansky and colleagues reported in Cellular and Molecular Neurobiology that the peptide, along with its Pro-Gly-Pro fragment, altered the transcription of neurotrophin and neurotrophin-receptor genes in rats subjected to permanent focal cerebral ischaemia, a standard surgical model of middle cerebral artery occlusion. The observation was a change in mRNA levels in affected brain tissue relative to controls. The study is relevant to laboratories because it suggests that the Pro-Gly-Pro tail contributes to the activity seen in animals. It can be found through a PubMed search for the Stavchansky study on Semax and Pro-Gly-Pro gene transcription after ischaemia.

The third area is monoaminergic signalling. Eremin and colleagues reported in Neurochemical Research that an ACTH(4-10) analogue with the Pro-Gly-Pro extension altered dopaminergic and serotonergic activity in rodent brain systems. The model was rodents with neurochemical measurements in defined regions, and the observation was a change in monoamine metabolism and release markers. Readers should note that the details of regions, timing and magnitude vary between experiments, and the original paper should be consulted before drawing quantitative comparisons.

The fourth area is a general one. Several groups have used transcriptome profiling, including microarray and sequencing approaches, to map how the peptide changes gene expression in rat brain tissue, particularly after experimental ischaemia. Reported changes involve genes associated with immune response, vascular function and neurotransmission. Because these datasets differ in design, tissue, time point and analytical pipeline, the area is best treated as a body of hypothesis-generating work rather than a single settled result. Independent replication outside the originating research community remains an open point in the literature.

Research applications

In neurobiology laboratories, the peptide is used as a pharmacological probe in rodent studies of neurotrophin regulation, particularly the BDNF-TrkB axis, and in studies of gene expression after experimental ischaemic injury. In vitro, it is applied to neuronal and glial cultures and to tissue preparations to examine transcriptional responses, with the caveat that findings from cultured cells do not automatically map onto whole-animal observations.

In neurochemistry, the compound is used to examine monoaminergic pathways, with measurements of neurotransmitter turnover in dissected brain regions. These experiments require a well-characterised peptide because small contaminants could confound results.

In peptide chemistry and pharmacokinetics, the heptapeptide serves as a model for how a terminal modification can slow enzymatic degradation. Researchers studying peptide stability in plasma, serum or tissue homogenates use it to compare half-lives and to identify breakdown products by liquid chromatography and mass spectrometry. The Pro-Gly-Pro motif makes it a useful case for exopeptidase resistance.

In analytical chemistry, it is used as a reference standard for method development, since its small size, defined sequence and oxidation-prone methionine make it a practical test case for HPLC gradients and for monitoring methionine sulfoxide formation by mass shift. In structural and biophysical work, short peptides of this kind are used in circular dichroism and NMR studies of conformational behaviour in solution.

Across these contexts, the shared requirement is material with documented identity, purity and batch history.

Purity, storage and handling

Verification begins with reversed-phase HPLC, which separates the target heptapeptide from synthesis-related impurities and reports purity as the percentage of total peak area at a stated wavelength, usually 214 or 220 nm. A purity figure is only meaningful when the chromatogram, gradient and detection conditions are supplied. Identity must be confirmed separately by mass spectrometry, where the observed mass should match the calculated value of roughly 813.9 daltons. For this sequence, laboratories should look specifically for a peak 16 daltons higher, which indicates methionine sulfoxide, the most likely oxidation product. The histidine and phenylalanine residues are less prone to chemical change but can influence retention behaviour. Net peptide content, determined by amino acid analysis or nitrogen analysis, is also important, because peptides purified with trifluoroacetic acid are supplied as TFA salts and the counterion contributes to the weight of the powder.

A batch-specific certificate of analysis matters because peptide synthesis is a per-run process. Yields, impurity profiles and salt content vary between syntheses, so a generic specification sheet describes an intention, while a batch certificate describes the powder in the vial. It should carry a lot number matching the label, method details and an analysis date. Because degradation accelerates once a peptide is reconstituted, batch-level HPLC verification matters more for an oxidation-prone sequence such as this one than for more robust peptides. UK laboratories sourcing Semax should expect a batch-specific certificate of analysis and lyophilised storage at -20 °C, and the same documentation standard applies when comparing the most trusted peptide supplier UK researchers may shortlist.

Lyophilised powder is the most stable form because the absence of water slows hydrolysis and microbial growth. Long-term storage at -20 °C is standard, with -80 °C used where maximum stability is required. Vials should equilibrate to room temperature in a desiccator before opening, because condensation on cold powder introduces moisture that shortens shelf life. Exposure should be brief and vials resealed promptly.

Light and oxygen are the main environmental concerns for this sequence. Methionine is susceptible to oxidation, and aromatic residues can be sensitive to photo-oxidation, so amber vials or foil wrapping and storage in the dark are sensible. Flushing the vial headspace with an inert gas such as nitrogen or argon before resealing is a common precaution for methionine-containing peptides.

Reconstituted peptide is far less stable than the dry powder. Solutions are best prepared in a buffer or solvent suited to the sequence, divided into single-use aliquots to avoid repeated freeze-thaw cycles, and stored frozen. Stability windows are short, often days to a few weeks, and should be established empirically for each solvent and temperature by repeat HPLC analysis. Low-binding tubes reduce losses through adsorption to plastic and glass. Dissolved oxygen in buffers can drive methionine oxidation, so degassed solvents are often used. Where microbial contamination is a concern, sterile filtration through a low-protein-binding membrane is a common step.

On receipt, laboratories should check that seals are intact, transfer the material to cold storage promptly, and record the receipt date and storage conditions against the lot number so that any later anomaly can be traced.

Frequently asked questions

What is the amino acid sequence and molecular weight of Semax?

The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a heptapeptide derived from an ACTH(4-10) fragment with a Pro-Gly-Pro tail. Its formula is C37H51N9O10S and its average molecular weight is about 813.9 daltons. Mass spectrometry should confirm this value, and a peak at plus 16 daltons indicates methionine oxidation.

How should lyophilised Semax be stored in a laboratory?

Lyophilised material is generally kept sealed, dry and protected from light at -20 °C for long-term storage, or colder for extended periods. Vials should warm to room temperature in a desiccator before opening to avoid condensation. Because the sequence contains methionine, minimising oxygen exposure is also good practice.

How stable is reconstituted Semax in solution?

Dissolved peptide degrades much faster than the lyophilised powder, mainly through methionine oxidation and hydrolysis. Stability depends on solvent, pH and temperature, so it should be tested by repeat HPLC. Single-use aliquots stored frozen, with repeated freeze-thaw cycles avoided, are the usual way to limit loss in research settings.

What should a certificate of analysis for a research peptide show?

A complete certificate lists the sequence, lot number, HPLC purity with chromatogram and method, measured versus theoretical mass, appearance and counterion form. Better documents add net peptide content, water content and endotoxin data where relevant, so that working concentrations can be calculated accurately for assays.

This peptide is supplied for in-vitro laboratory research only. It is not a medicine, is not intended for human or veterinary use, and must not be administered to people or animals. Researchers remain responsible for complying with institutional, safety and regulatory requirements in the UK.